Predicting liver cancer risk in hepatitis B-related liver disease
Part of Cancer, Digestive system, Infections clinical trials.
This study is testing a new way to predict if people with chronic hepatitis B, who also have liver fibrosis or cirrhosis, might develop liver cancer (HCC). It uses your medical data to create a risk score, which could help you and your doctor plan earlier and more tailored monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver fibrosis or cirrhosis caused by hepatitis B.
- You are taking antiviral medication for hepatitis B.
- You have been followed by your doctor for at least 6 months, with at least two follow-up visits.
- You have not had liver cancer (HCC) or a liver transplant recently (within the last 6 months).
- You do not have other liver diseases like fatty liver, drug-induced liver injury, or genetic metabolic liver disease, and you do not have other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This study aims to predict the risk of developing liver cancer in people with chronic liver conditions such as hepatitis B or C, cirrhosis, or fatty liver disease. By participating, you may help researchers improve early detection and prevention strategies for liver cancer.
This study looks at your risk of developing liver cancer if you have hepatitis B. It uses your medical history and test results to give you a better idea of your risk and help guide next steps.
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
This study looks at your risk of developing liver cancer (hepatocellular carcinoma) if you have a liver condition such as NAFLD or a related disease. It aims to improve how doctors predict who might be at higher risk, so they can offer better monitoring and care.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.